Introduction
============

Lung cancer is one of the most common cancers and is a leading cause of morbidity and mortality worldwide[@B1]. Although antismoking policies have resulted in a reduction in smoking rate, the incidence of lung cancer continues to increase[@B2][@B3]. In addition, the proportion of never-smokers developing lung cancer is higher than before[@B4]. Although recent studies show that the epidemiology of lung cancer in Korea has changed in line with international observations[@B3][@B5], few studies provide clinical information on lung cancer based on nationwide registry.

The first national lung cancer survey in Korea was conducted in 1997 by the Korean Academy of Tuberculosis and Respiratory Diseases, at which point squamous cell carcinoma was the most frequent histological subtype[@B6]. However, the second national lung cancer survey conducted by the Korean Association for the Study of Lung Cancer in 2005 showed that adenocarcinoma was the most common histological subtype and that the absence of symptoms at diagnosis was a favorable prognostic factor for patients with non-small cell lung cancer (NSCLC)[@B7]. Because the clinical characteristics and outcomes of patients with lung cancer were expected to differ over time, we analyzed data from a population-based nationwide cancer registry. In this study, we aimed to investigate the clinical characteristics, histological types, and prognostic factors associated with lung cancer in Korea.

Materials and Methods
=====================

1. Study populations and methods
--------------------------------

In 2013, 23,254 new cases of lung cancer were registered nationwide at Korean Central Cancer Registry (KCCR). To investigate the detailed clinical characteristics, treatment information, and outcomes of Korean lung cancer patients, the Korean Association for Lung Cancer (KALC) and KCCR selected data using systematic sampling method for initial analysis. First, 12 national or regional cancer centers were selected according to the number of lung cancer patients. Subsequently, two additional hospitals were selected by the KCCR and five by the KALC. Each of the national or regional cancer centers and the two hospitals selected by the KCCR recruited 10--20 patients; the five hospitals selected by the KALC registered approximately 50 patients.

Data regarding age, sex, body mass index (BMI), smoking history, histopathologic type, symptoms, performance status (PS), Eastern Corporative Oncology Group score, clinical stage (according to the seventh edition of the TNM International Staging System), treatment modality, and survival status were collected according to a standardized protocol. Patients were followed up until October 2016. Survival data for all patients were obtained from medical records, telephone interviews, and/or the record of National Health Insurance of Korea. The study protocol was reviewed and approved by the Institutional Review Board at the National Cancer Center. Informed consent was waived due to the retrospective nature of the study.

2. Statistical analysis
-----------------------

Comparison of baseline characteristics between survivor and non-survivor was performed using a Mann--Whitney U test for continuous variables and a chi-square or Fisher exact test for categorical data. All p-values were two-tailed, with statistical significance set at p\<0.05. Risk factors for mortality were analyzed using the Cox proportional hazards model, and Kaplan-Meier survival analysis was used to evaluate differences in survival rates. Statistical analyses were performed using SPSS version 20.0 for Windows (IBM Corp., Armonk, NY, USA).

Results
=======

1. Patient characteristics
--------------------------

A total of 489 lung cancer patients were enrolled at the 19 sites, the baseline characteristics of which are summarized in [Table 1](#T1){ref-type="table"}. The median patient age was 69 years (interquartile range, 60--74 years), 65.4% of patients were male, and 62.1% of patients were ever-smokers. Of the male patients, 88.6% were former or current smokers, while only 11.5% of the female patients had a history of smoking. Cough (33.5%) was the most common symptom at the time of diagnosis, and 13.1% of patients were asymptomatic. Among patients with NSCLC, proportions of asymptomatic patients in each clinical stage were 29.2% (in stage I), 20.5% (in stage II), 7.0% (in stage III), and 6.3% (in stage IV), respectively. PS score data were available from 351 patients, and 14.2% of patients showed poor PS (PS ≥2). The proportion of NSCLC patients at each clinical stage was as follows: stage I, 25.6%; stage II, 9.5%; stage III, 22.9%; and stage IV, 42.0%. According to the sex, the clinical stages of NSCLC patients were I (19.0%), II (9.0%), III (28.0%), and IV (44.0%) in male patients and I (28.8%), II (9.6%), III (10.3%), and IV (51.3%) in female patients, respectively. In small cell lung cancer (SCLC) patients, 36.8% were at a limited stage of disease and 52.6% were at an extensive stage. Among patients with adenocarcinoma, epidermal growth factor receptor (*EGFR*) mutations were found in 13.4% of patients and 31.7% of patients performed *EGFR* mutation test, respectively. A total 76.5% of patients were treated by surgery, chemotherapy, or radiation therapy.

During follow-up, there were 277 patient deaths (56.6%). The non-survival group was characterized by older age, a higher proportion of males, lower median BMI, and a higher proportion of ever-smokers when compared with the surviving group. In addition, the non-survival group had fewer asymptomatic patients, lower PS, and a higher incidence of metastatic disease than patients who survived the follow-up period. The surviving group had a higher proportion of patients who received treatment, particularly surgery.

2. Histological classification
------------------------------

In the overall population, the most frequent histological subtype was adenocarcinoma (48.7%), followed by squamous cell carcinoma (27.2%) and SCLC (11.5%). While squamous cell carcinoma (37.2%) was the leading subtype in male patients, adenocarcinoma showed the highest incidence in female patients, accounting for 76.3% of lung cancers ([Figure 1](#F1){ref-type="fig"}).

3. Initial treatment
--------------------

In patients with NSCLC, 47.2% of patients underwent surgery, followed by chemotherapy (27.9%) and radiation therapy (23.7%), after initial diagnosis. By contrast, chemotherapy (69.8%) was the most common treatment modality in patients with SCLC and only four patients received surgery after the initial SCLC diagnosis ([Table 2](#T2){ref-type="table"}).

4. Risk factors for mortality
-----------------------------

The median follow-up period was 504 days (interquartile range, 182--1,038 days). On univariate Cox analysis, age, male sex, lower BMI, smoking history, absence of symptoms, weight loss, poor PS, SCLC, metastatic disease, and no treatment were all significant predictors of mortality in patients with lung cancer. In multivariate Cox analysis, age, lower BMI, smoking history, absence of symptoms, SCLC, metastatic disease, and no treatment were seen to be meaningful predictors of mortality in total subjects ([Table 3](#T3){ref-type="table"}).

While treatment, age, and weight loss were significant prognostic factor in stage I--II NSCLC patients, meaningful prognostic factor in stage III--IV NSCLC patients were treatment status, age, sex, BMI, and PS. In addition, although proportion of asymptomatic patients in stage III--IV NSCLC was relatively low, absence of symptoms was significant prognostic factor in these patients ([Supplementary Table S1](#S1){ref-type="supplementary-material"}).

When underweight patients (BMI \<18.5) were evaluated in total patients, Kaplan-Meier survival analysis showed that the survival period of this sub-population was significantly shorter than that of the remaining patients (p\<0.001) ([Figure 2](#F2){ref-type="fig"}).

Discussion
==========

This study evaluated the characteristics and recent trends among lung cancer patients in Korea, showing that lung cancer occurs predominantly in elderly patients (median age, 69 years). In addition, histological and clinical characteristics differed from those in the two previous nationwide surveys. Ever-smokers, the elderly, those with a low BMI, and patients with advanced lung cancer had a poor clinical outcome, while asymptomatic patients and those who received anti-tumor treatment had a favorable prognosis.

According to the KCCR, 23,254 new lung cancer cases were diagnosed in Korea in 2013 (men, 69.8%; women, 30.2%)[@B8]. The crude incidence rate was 45.8 per 100,000, and the age-standardized lung cancer incidence rate (age-adjusted to the world standard population) was 27.4 per 100,000. In addition, lung cancer (crude mortality rate, 49.5 per 100,000) was the leading cause of death in both sexes. However, the 5-year relative survival rate for lung cancer has increased from 11.3% (1993--1995) to 23.5% (2009--2013).

The incidence of adenocarcinoma had been increasing in both men and women, and it is the most common type of lung cancer in Korea. This finding is in agreement with previous studies worldwide, and there are some possible hypotheses for this observation[@B9][@B10]. First, the development of low-tar and filtered cigarettes may result in smokers inhaling more deeply, which promotes peripheral tumors such as adenocarcinoma[@B11]. Also, changes in cigarette composition, such as an increase in the dose of potent tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), may have contributed to the rising incidence in adenocarcinoma[@B12][@B13]. However, in the present study, a substantial proportion of adenocarcinoma cases (58.5%) occurred in patients who had never smoked, and occupational risk, air pollution, and genetic susceptibility could, therefore, be risk factors in these patients[@B14][@B15][@B16].

The median age of our study population was 69 years, and the age at diagnosis was higher than that observed in the two previous nationwide studies in Korea[@B6][@B7]. Although younger patients have a more favorable prognosis than older patients in general[@B7][@B17], the incidence of lung cancer in the elderly is expected to continue to increase[@B18]. In addition, older age may in itself be an important treatment consideration due to physiologic changes associated with aging, a variety of comorbidities, and toxicities associated with treatment[@B19]. To clarify these considerations, further studies focusing on elderly patients will be required.

Smoking is a well-established cause of lung cancer[@B20]. According to the Korea National Health and Nutrition Examination Survey, the prevalence of current cigarette smoking in 2013 was 42.1% in male adults and 6.2% in females[@B21]. Although the smoking rate has been decreasing in men, no significant change was seen in women[@B2][@B21]. In agreement with previous studies, smoking was seen to be an independent prognostic factor in the present study, even after adjustment[@B22][@B23][@B24]. It would appear that vigorous antismoking policies, such as smoking cessation medication and motivational interviewing, are still required to reduce the rate of smoking among both sexes[@B25][@B26].

Our data, when compared with those of previous studies, showed that the proportion of female lung cancer patients has been steadily increasing in Korea, and recent studies suggest that some genetic and hormonal factors may play a role[@B27][@B28][@B29]. In addition, the proportion of patients with stage I--II NSCLC and good performance (PS 0--1), and asymptomatic patients, was higher. These results may reflect improved lung cancer screening processes, including low-dose computed tomography (CT) in high risk patients[@B30]. An increase in the proportion of patients with stage IV NSCLC could be explained by the use of positron emission tomography with CT and brain magnetic resonance imaging, also possibly as a result of changing TNM stage[@B31][@B32].

Over three-quarters of patients received treatment including surgery, radiation therapy, and chemotherapy. As almost half of the NSCLC patients received surgery, this may have resulted in the improved prognosis seen in NSCLC patients compared with SCLC patients, in the present study. Also, a number of molecularly targeted therapies and immune checkpoint inhibitors have become available for use in clinical practicerecently[@B33][@B34], further studies are required to evaluate the efficacy of these new agents in Korean patients.

Interestingly, low BMI was associated with poor outcome, particularly in underweight patients. Although previous studies showed similar results[@B35][@B36], the precise mechanism underlying this observation has not yet been clarified. These findings are, however, comparable to those of other chronic lung diseases, such as chronic obstructive lung disease and idiopathic pulmonary fibrosis[@B37][@B38], and a possible explanation may be related to the effect of several cytokines or malnutrition[@B39][@B40]. The association between mortality and low BMI in lung cancer patients requires further evaluation in future studies.

There are several limitations to this study. First, our analysis was based on a sample of the full database and the study number was relatively small. Although patients were included from 19 centers, it may not be possible to generalize our results to the full population. Secondly, due to the retrospective design, some clinical information could not be extracted. Also, social factors and comorbid conditions were unavailable for most patients and this could have resulted in unknown bias. However, this population-based study will help to understand changes in the epidemiology of lung cancer in Korea over time and serve as reference for future studies.

In conclusion, the characteristics of lung cancer in Korea have changed over time, showing an increase in the proportion of adenocarcinoma, female patients, asymptomatic status, and early stage lung cancer. Our data also show that prognosis is poorer in ever-smokers, the elderly, and malnourished and untreated patients with advanced lung cancer. Future advancement in the management of lung cancer requires early detection and individualized therapy.
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###### Supplementary Table S1

Risk factor for mortality in patients with NSCLC according to clinical stage assessed by Cox proportional hazards model

![Proportion of lung cancer histological type based on Korean Nation-wide Lung Cancer Registry. (A) In total patients. (B) In male gender. (C) In female gender. NSCLC NOS: non-small cell lung cancer not otherwise specified.](trd-82-118-g001){#F1}

![Kaplan-Meier survival curves of the lung cancer patients with under-weight (BMI \<18.5 kg/m^2^) and others (BMI ≥18.5 kg/m^2^).](trd-82-118-g002){#F2}

###### Baseline characteristics of lung cancer patients

![](trd-82-118-i001)

  Characteristic                               Total (n=489)      Survivor (n=212)   Non-survivor (n=277)   p-value
  -------------------------------------------- ------------------ ------------------ ---------------------- ---------
  Age                                          69 (60‒74)         63 (56‒72)         71 (64‒76)             \<0.001
  Male sex                                     320 (65.4)         120 (56.6)         200 (72.2)             \<0.001
  BMI, kg/m^2^                                 22.6 (20.3‒24.7)   23.4 (21.2‒25.3)   22.1 (19.7‒24.0)       \<0.001
  Ever smoker                                  298 (62.1)         108 (52.2)         190 (69.6)             \<0.001
  Symptoms                                                                                                  
   Asymptomatic                                64 (13.1)          48 (22.6)          16 (5.8)               \<0.001
   Cough                                       164 (33.5)         53 (25.0)          111 (40.1)             \<0.001
   Sputum                                      114 (23.3)         39 (18.4)          75 (27.1)              0.024
   Dyspnea                                     99 (20.2)          30 (14.2)          69 (24.9)              0.003
   Hoarseness                                  4 (0.8)            1 (0.5)            3 (1.1)                0.637
   Hemoptysis                                  32 (6.5)           15 (7.1)           17 (6.1)               0.678
   Weight loss                                 33 (6.7)           10 (4.7)           23 (8.3)               0.117
  Performance status                                                                                        \<0.001
   0--1                                        301 (85.8)         140 (94.0)         161 (79.7)             
   2--4                                        50 (14.2)          9 (6.0)            41 (20.3)              
  Clinical staging (NSCLC)                                                                                  \<0.001
   I                                           94 (25.6)          87 (52.1)          7 (3.5)                
   II                                          35 (9.5)           23 (13.8)          12 (6.0)               
   III                                         84 (22.9)          29 (17.4)          55 (27.5)              
   IV                                          154 (42.0)         28 (16.8)          126 (63.0)             
  Clinical staging (SCLC)                                                                                   0.001
   Limited                                     21 (36.8)          9 (90.0)           12 (25.5)              
   Extensive                                   30 (52.6)          1 (10.0)           29 (61.7)              
   Unknown                                     6 (10.5)           0 (0)              6 (12.8)               
  *EGFR* mutation status (in adenocarcinoma)                                                                0.697
   Positive                                    32 (13.4)          18 (12.5)          14 (14.9)              
   Negative                                    69 (29.0)          40 (27.8)          29 (30.9)              
   Not checked                                 137 (57.6)         86 (59.7)          51 (54.3)              
  Any treatment after diagnosis                374 (76.5)         189 (89.2)         185 (66.8)             \<0.001

Values are expressed are expressed as number (%) or median (interquartile range).

BMI: body mass index; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; EGFR: epidermal growth factor receptor.

###### Initial treatment of patients with lung cancer

![](trd-82-118-i002)

                       NSCLC (n=316)   SCLC (n=43)   p-value
  -------------------- --------------- ------------- ---------
  Treatment modality                                 \<0.001
   Operation           149 (47.2)      4 (9.3)       
   Radiation therapy   75 (23.7)       9 (20.9)      
   Chemotherapy        88 (27.9)       30 (69.8)     
   CCRT                4 (1.3)         0 (0)         

Values are expressed are expressed as number (%)

NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; CCRT: concurrent chemoradiation therapy.

###### Risk factor for mortality in patients with lung cancer assessed by Cox proportional hazards model

![](trd-82-118-i003)

  Parameter                           HR      95% CI         p-value
  ----------------------------------- ------- -------------- ---------
  Univariate analysis                                        
   Age                                1.048   1.035--1.061   \<0.001
   Male sex                           1.751   1.345--2.280   \<0.001
   Under weight patient (BMI\<18.5)   2.009   1.384--2.915   \<0.001
   BMI, kg/m^2^                       0.906   0.869--0.945   \<0.001
   Ever smoker                        1.714   1.323--2.220   \<0.001
   Asymptomatic patient               0.265   0.160--0.439   \<0.001
   Weight loss                        1.577   1.029--2.417   0.037
   Performance status 2--4            3.135   2.206--4.456   \<0.001
   Small cell lung cancer             2.488   1.807--3.425   \<0.001
   Distant metastasis                 4.142   3.179--5.397   \<0.001
   Any treatment                      0.242   0.187--0.314   \<0.001
  Multivariate analysis                                      
   Age                                1.037   1.020--1.055   \<0.001
   BMI, kg/m^2^                       0.904   0.864--0.945   \<0.001
   Ever smoker                        2.003   1.394--2.876   \<0.001
   Asymptomatic patient               0.387   0.195--0.765   0.006
   Small cell lung cancer             1.627   1.077--2.458   0.021
   Distant metastasis                 3.990   2.812--5.661   \<0.001
   Any treatment                      0.364   0.253--0.522   \<0.001

HR: hazard ratio; CI: confidence interval; BMI: body mass index.
